Fourteen healthy subjects completed an experiential session after receiving 25 mg psilocybin – Results of this phase I study will inform the design […]
Read more
CALGARY, AB, Jan. 7, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”) has been granted a No Objection Letter (“NOL”) by Health […]
Read more
ATMA Journey Centers have applied for Health Canada approval to provide experiential training to mental health professionals interested in learning how to provide psychedelic-assisted psychotherapy.
Read moreJoin our newsletter for the latest updates, insights, and exclusive offers on everything psychedelic therapy.
